AbbVie Inc.

🇺🇸New York Stock Exchange
Back to all articles
AbbVie Inc. stock analysis ABBV overview
Bullish +75

5 Best Cheap Stocks to Buy for Beginners

🧬 AbbVie Inc. (NYSE: ABBV) is highlighted as one of the best cheap stocks for beginners in this article.

💊 The European Commission approved AQUIPTA on June 2 for acute migraine treatment in adults with or without aura.

🛡️ AQUIPTA now holds dual approval as both an acute treatment and a once-daily preventive option for chronic or episodic migraine patients.

🔬 VENCLYXTO received expanded label authorization from the European Commission on May 29 for use with acalabrutinib or ibrutinib.

🩸 The expanded VENCLYXTO label covers treatment for adult patients with previously untreated chronic lymphocytic leukemia (CLL).

🏥 AbbVie is a research-based pharmaceutical company developing products for oncology, gastroenterology, rheumatology, dermatology, and virology.

📉 The article lists other cheap stocks like Sandisk, Moderna, Abivax, Navitas, PureCycle, and POET Technologies as top picks.

📈 Sandisk is noted to have soared to an all-time high with a 4,573% gain over one year.

🧬 Moderna climbed 7.5% ahead of key updates expected next week.

🚀 Abivax skyrocketed 24% following a steep fall in its stock price.

💻 Navitas hit an all-time high potentially due to Nvidia-related developments.

🔋 PureCycle added 6% on the success of its PureFive Living Hinge Cap.

🏭 POET Technologies soared 11%, mimicking the broader industry rally.

📊 Insider Monkey's quarterly strategy is reported to have returned +498.7%.

📈 The benchmark for comparison includes a 50% S&P 500 ETF and 50% Russell 2000 ETF with +195% returns.

📅 Returns data covers the period from May 2014 through February 18th, 2026.

🔒 A 30-day money-back guarantee is offered for subscribing to the service.

🚫 Readers are directed to visit a separate link for an extended list and methodology behind the picks.

Bullish Signals
  • AbbVie Inc. (NYSE: ABBV) received European Commission approval on June 2 for AQUIPTA as a once-daily preventive treatment option for adults with chronic or episodic migraine who experience four or more migraine days per month.
  • The company secured authorization on May 29 for an expanded label for VENCLYXTO to include use in combination with acalabrutinib and ibrutinib to treat adult patients with previously untreated chronic lymphocytic leukemia (CLL).
  • Management highlighted that the VENCLYXTO expansion follows the European Commission's inclusion of these combinations in the acalabrutinib and ibrutinib labels, reinforcing all-oral, fixed-duration combination regimens as current standards of care.
  • AbbVie continues to develop and sell products across multiple therapeutic areas including oncology, gastroenterology, rheumatology, dermatology, and virology.
Full Analysis
AbbVie Inc. (NYSE: ABBV) has received regulatory approvals for two of its key products in the European Union, marking significant milestones for its pipeline. On June 2, the European Commission approved AQUIPTA for the acute treatment of migraine in adults with or without aura. This approval represents the second indication for the drug in the EU, expanding its role as both an acute treatment option and a once-daily preventive treatment for adults suffering from chronic or episodic migraine who experience four or more migraine days per month. In a separate development announced on May 29, AbbVie secured authorization from the European Commission to expand the label for VENCLYXTO. This expanded indication allows for use in combination with acalabrutinib (with or without obinutuzumab) and ibrutinib to treat adult patients with previously untreated chronic lymphocytic leukemia (CLL). The company noted that these fixed-duration, all-oral combination regimens align with current standards of care following the EC's inclusion of these combinations in the acalabrutinib and ibrutinib labels. AbbVie is a research-based pharmaceutical company focused on developing and selling products to treat chronic diseases across various therapeutic areas, including oncology, gastroenterology, rheumatology, dermatology, and virology. These regulatory wins reinforce its position in the European market for both migraine management and oncology treatments.